Please login to the form below

Not currently logged in
Email:
Password:

Johan Heylen leaves GSK for Ablynx

He joins Nanobody specialist as chief commercial officer

edit-Johan-Heylen_Chief-Commercial-Officer_AblynxAblynx has named former GlaxoSmithKline (GSK) executive Johan Heylen as chief commercial officer.

Heylen spent 17 years at GSK, serving most recently as executive director, global commercial lead for its cancer immunotherapeutics division.

In this role he headed the global commercial teams of GSK and was responsible for the development and implementation of the launch strategy for several drugs, including Rotarix, Priorix and Varilix.

Heylen now heads commercial operations at Ablynx, growing biopharma specialising in the development of Nanobodies, tiny fragments of antibodies with therapeutic potential.

He said: "Ablynx has an extraordinary pipeline of products based on its unique Nanobody discovery platform, validated by an impressive list of partners.

“I look forward to working with the first-class team to support the company as it moves to the next stage of development and begins to anticipate the commercialisation of the first Nanobody-based therapeutics."

Heylen also has experience at Servier and Wyeth having started his career in healthcare as a pharmacist.

20th November 2014

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics